VIDEO: Better understanding of Bruch’s membrane may help development of AMD treatments
Click Here to Manage Email Alerts
SEATTLE — In this video, Eleonora M. Lad, MD, PhD, discusses how targeting abnormalities in Bruch’s membrane in patients with age-related macular degeneration may aid in the development of treatments.
In a session co-moderated by Christopher B. Toomey, MD, PhD, at the ARVO annual meeting, experts discussed new developments in understanding Burch’s membrane.
The membrane serves as a filter and barrier and is affected by aging, according to Lad, vice chair of ophthalmology clinical research at Duke Health.
“[Toomey’s] lab found that Bruch’s membranes in early and intermediate AMD in patients [have] a larger amount of heparan sulfate. This has a high affinity for apolipoproteins, those lipid deposits that accumulate,” Lad said. “Perhaps targeting these Bruch’s membrane abnormalities will help in the future in the development of treatments in AMD.”
Reference:
- Toomey C, et al. Metabolic pathways and dynamics in retina/RPE. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.